Explore / Clinical trial
Clinical trial

Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA

Peking University First HospitalCompletedPhase 4Started Sep 11, 2024100 enrolledChinaNCT06566482

Abstract

Patients with obstructive sleep apnea (OSA) are at increased risk of developing sleep disturbances after surgery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, analgesic, and anxiolytic effects. Ketamine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine and twice as potent as racemic ketamine for analgesia. A recent trial showed that mini-dose esketamine-dexmedetomidine in combination with opioids improved analgesia and subjective sleep quality after scoliosis correction surgery. This trial is designed to test the hypothesis that mini-dose dexmedetomidine-esketamine supplemented analgesia may improve postoperative sleep quality in patients at high-risk of OSA.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineAnxiety

Keywords

Obstructive Sleep ApneaSurgeryDexmedetomidineEsketaminePostoperative sleep qualityObstructive Sleep ApneaSurgeryDexmedetomidineEsketaminePostoperative Sleep Quality

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.